► to work for just eight hours a week and only on experiments “that would cost more to shut down than to continue”. He says his lab studies “mouse plague”: *Yersinia pseudotuberculosis*, which in mice causes cysts and gut problems over the course of two to three months. The disease progression cannot be rescheduled, he says, and most researchers did not count on a shutdown when they started their experiments months ago. With just two people at a time in the lab, some parts of the experiments may go unfinished.

Researchers working on animals are among the most worried. One postdoc from the National Cancer Institute says that her security access was revoked at first, but after her adviser pleaded her case, she was given permission to enter her building for one hour per day to advise the technicians who are caring for her mice. The rodents were injected with cancerous cells several months ago, she says, and some of their tumours have now grown so large that the animals need to be killed. She is grateful for that one hour, she says, because it allows her to direct the technicians to take tissue biopsies so that she will be able to pick her experiment back up once the shutdown ends.

Other animal researchers say that the shutdown is affecting their projects in more unpredictable ways. One NIH scientist who works with primates says that it is keeping him from retrieving samples from the primate facilities in Poolesville, Maryland, 40 kilometres from Bethesda. Regulations require that animal-tissue specimens be transported in a government car, but the shutdown has kept government vehicles out of use. And if he cannot do his work, which involves human therapeutics, the researcher questions the morality of keeping the primates. “I don’t think it’s ethical to have an animal in a cage if we’re not doing experiments on it,” he says.

There is one place on campus that still seems to be doing good business: the small cafeteria in the NIH’s Clinical Center. Normally used by patients, it is now the only place open to eat. The buzz of conversation there seems muffled. Discussions of science are overshadowed by doubt, worry and uncertainty. ■

NOBEL PRIZE

Modellers react to chemistry award

Prize proves that theorists can measure up to experimenters.

BY RICHARD VAN NOORDEN

Computer modelling is one of the many scientific fields that Alfred Nobel, understandably, failed to anticipate in his 1895 will. And so, as Michael Levitt points out, “there’s no Nobel prize for computer science”. But computation’s increasing importance in chemistry and biology was recognized last week, when Levitt, of Stanford University in California, was one of three scientists to receive the chemistry Nobel for their work on ways to simulate the activity of large molecules — from cellular enzymes to light-absorbing dyes.

“Computers in biology have not been sufficiently appreciated,” Levitt said at a press conference, joking that a fourth portion of the Nobel might have gone to the chip manufacturers, who have driven up computing power exponentially.

Together with Martin Karplus of the University of Strasbourg in France and Harvard University in Cambridge, Massachusetts, and Arieh Warshel of the University of Southern California in Los Angeles, Levitt was honoured for a specific modelling technique: working out how to stitch together descriptions of molecules at close-up and zoomed-out scales.

The three were trailblazers in the 1970s. At the time, finely detailed quantum-mechanical pictures of bond making and breaking could not be calculated for more than a cluster of atoms — even today they are too complex to be computable beyond a few hundred atoms, and cannot be used to model whole proteins. So Levitt, Warshel and Karplus worked out how to merge these models with simplified simulations that treat molecules as non-reacting, vibrating atomic balls

connected by springs. “The art is to find an approximation simple enough to be computable, but not so simple that you lose the useful detail,” Levitt says.

These multi-scale models have proved essential for studying the workings of enzyme reactions, and were pioneered in a 1976 paper in which Warshel and Levitt explained how lysozyme cleaves a glycosidic bond. Multi-scale techniques are not widely used in the drug industry, adds Kenneth Merz, who heads the Institute for Cyber-Enabled Research at Michigan State University in East Lansing. Instead, says theorist Christopher Cramer of the University of Minnesota in Minneapolis, they find uses in, for example, revealing how industrial catalysts work, or examining how light activates dyes on semiconducting nanoparticles.

The award is also being viewed as an acknowledgement of the three scientists’ lifetime work in molecular simulation, researchers told *Nature*. “They have made theory an equal partner to experiment,” said theoretical chemist Gunnar Karlström of Lund University in Sweden, a member of the Nobel committee.

Still, a question mark remains over whether theorists can make predictions that surprise experimenters. Computer modelling “is really good at helping people understand why things work the way they do, but not so good at predicting new things. We are good at guiding experimentalists,” says Ken Houk, who uses computer programs to design new enzymes at the University of California, Los Angeles.

Experimenters should be cautious of simulation results, agrees Warshel. But “one day everything will be done by powerful computers”, he predicts.

Cramer adds: “Every year, hazardous-waste disposal gets more expensive, whereas computing power gets cheaper. So the progress curves favour the theoreticians.” ■

“We are good at guiding experimentalists.”

MORE ONLINE

VIDEO OF THE WEEK

Mammals chop up viral RNA to attack infection
go.nature.com/sftmsh

MORE NEWS

- Quantum wavefunction collapse caught in slow motion go.nature.com/ryu8ny
- Diamond drizzle forecast for Saturn and Jupiter go.nature.com/r1pwmr
- Ozone loss warmed southern Africa go.nature.com/ph2nyo

TOP STORY

Live updates on how science is being hit by the US government shutdown
go.nature.com/u5kntz